Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $590
Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $500 to $590.
Read original at benzingaStocks · News reference
The Capitol Forum Posts On X "Chemed: Vitas Healthcare Misdiagnosed Dementia Patients and 'Fudged' Evaluation Scores in Order to Admit Them into Hospice; Expert Who Reviewed Internal Documents Says They Warrant Federal Investigation"
https://x.com/Capitol_Forum/status/2093021234103488646
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 5:14 PM
- Checked
- Aug 27, 2026, 5:14 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
RBC Capital Maintains Sector Perform on Chemed, Raises Price Target to $548
Read original at benzinga8-K filing — CHEMED CORP (CHE)
Filed: 2026-07-28 AccNo: 0000019584-26-000018 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar